Print this page    •   Back to Web version of article

International News
Reuters Examines Increase in Drug Trials Abroad

May 9, 2011

In a special report on global drug trials, Reuters reports that pharmaceutical companies are "seek[ing] cheaper venues for studies and cast[ing] their net further afield for big pools of 'treatment-naive' patients who are not already taking other drugs that could make them unsuitable subjects for testing new ones. ... The drug industry is also paying a lot more attention these days to the promise of emerging markets, whose healthcare authorities, just like those in the United States and Western Europe, are keen to see cutting-edge science conducted in their backyards." The article looks at some of the questions raised as clinical trials increase in areas like Eastern Europe, Asia and Latin America: "Is the quality of the data as reliable as that from a top U.S. medical center? Is it safe to extrapolate common clinical effects from studying patients with different lifestyles and genetic profiles? And are ethical standards in testing new drugs properly upheld in poorer countries?" (Hirschler, 5/6).

Back to other news for May 2011

This information was reprinted from with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.